| Literature DB >> 24971333 |
Filip Cečka1, Bohumil Jon1, Zdeněk Subrt2, Alexander Ferko1.
Abstract
Despite recent improvements in surgical technique, the morbidity of distal pancreatectomy remains high, with pancreatic fistula being the most significant postoperative complication. A systematic review of randomized controlled trials (RCTs) dealing with surgical techniques in distal pancreatectomy was carried out to summarize up-to-date knowledge on this topic. The Cochrane Central Registry of Controlled Trials, Embase, Web of Science, and Pubmed were searched for relevant articles published from 1990 to December 2013. Ten RCTs were identified and included in the systematic review, with a total of 1286 patients being randomized (samples ranging from 41 to 450). The reviewers were in agreement for application of the eligibility criteria for study selection. It was not possible to carry out meta-analysis of these studies because of the heterogeneity of surgical techniques and approaches, such as varying methods of pancreas transection, reinforcement of the stump with seromuscular patch or pancreaticoenteric anastomosis, sealing with fibrin sealants and pancreatic stent placement. Management of the pancreatic remnant after distal pancreatectomy is still a matter of debate. The results of this systematic review are possibly biased by methodological problems in some of the included studies. New well designed and carefully conducted RCTs must be performed to establish the optimal strategy for pancreatic remnant management after distal pancreatectomy.Entities:
Mesh:
Year: 2014 PMID: 24971333 PMCID: PMC4058114 DOI: 10.1155/2014/482906
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Flowchart of the literature search strategy.
The main characteristics and results of the selected trials.
| Reference | Year | Age | Sex (M/F) | Definition of pancreatic fistula | Interventions | Group size | Mortality | Morbidity | Fistula rate |
| |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Suzuki et al. [ | 1995 | SC | 58,7 ± 15,5* | 19/7 | Any amount, concentration 3x normal serum value lasting for at least 7 days | Fibrin glue | 26 | 1,8% | N/A | 15,4% | 0,04 |
|
| |||||||||||
| Suzuki et al. [ | 1999 | SC | 57,7 ± 10,9* | 18/9 | Any amount, concentration 3x normal serum value lasting for at least 7 days | Ultrasonic dissection | 27 | N/A | N/A | 3,7% | 0,02 |
|
| |||||||||||
|
Bassi et al. [ | 1999 | SC | N/A | N/A |
More than 10 mL/d with | Suture closure | 15 | 0% | N/A | 33,3% | NS |
| N/A | N/A | Suture closure + fibrin glue | 11 | 0% | N/A | 27,3% | |||||
| N/A | N/A | Suture closure + polypropylene mesh | 15 | 0% | N/A | 13,3% | |||||
| N/A | N/A | Pancreaticojejunostomy | 14 | 0% | N/A | 7,1% | |||||
| N/A | N/A | Stapler closure | 14 | 0% | N/A | 14,3% | |||||
|
| |||||||||||
|
Suc et al. [ | 2003 | MC | N/A | N/A | Any amount, concentration 4x normal serum value lasting for at least 3 days | Occlusion of the main duct with fibrin glue | 22 | 0% | 27,20% | 18,2% | NS |
| N/A | N/A | Control group | 19 | 5,3% | 26,30% | 15,8% | |||||
|
| |||||||||||
|
Oláh et al. [ | 2009 | SC | 65 (52–70)** | 21/14 | ISGPF | Stapler + seromuscular patch | 35 | 0% | 11,4%+
| 8,6% | N/A |
|
| |||||||||||
| Diener et al. [ | 2011 | MC | 59,8 ± 14,1* | 85/92 | ISGPF | Stapler | 177 | <1% | 49,2% | 35,6% | 0,84 |
|
| |||||||||||
| Frozanpor et al. [ | 2012 | SC | N/A | 12/15 | ISGPF | Distal pancreatectomy | 27 | 0% | 100,0% | 37,0% | 0,122 |
|
| |||||||||||
| Hamilton et al. [ | 2012 | SC | 58,6 ± 13,4* | 25/21 | More than 50 mL/d, concentration 3x normal serum value after day 3 | Stapler | 46 | 0% | 60,9% | 56,5% | 0,001 |
|
| |||||||||||
| Montorsi et al. [ | 2012 | MC | 60,5 ± 14,9* | 64/81 | ISGPF | TachoSil | 145 | 0% | 28,3%++
| 62,1% | 0,267 |
|
| |||||||||||
| Carter et al. [ | 2013 | DC | 62,5 (29–84)*** | 22/28 | ISGPF | Falciform patch and fibrin glue | 50 | 0% | N/A | 20,0% | 1 |
SC: single center, MC: multicenter, DC: dual-center, N/A: not available, NS: not significant, *mean ± standard deviation, **median (interquartile range), ***median (range), +pancreas-related morbidity, ++postoperative complications excluding POPF.
Assessment of methodological quality and risk of bias of the selected trials.
| Reference | Year | Group size calculation | Randomization and concealment of allocation | Blinding | Complete | Risk of bias |
|---|---|---|---|---|---|---|
| Suzuki et al. [ | 1995 | Missing | Drawing lots | Missing | Missing | High |
|
| ||||||
| Suzuki et al. [ | 1999 | Missing | Drawing lots | Missing | Missing | High |
|
| ||||||
| Bassi et al. [ | 1999 | Missing | Missing | Missing | Missing | High |
|
| ||||||
| Suc et al. [ | 2003 | POPF rate 40%, reduction to 20%, one-tailed test alfa 5%, power of 80% | Telephone call to the coordinating center, computerized random-number tables | Patients and nursing staff | 30 days after discharge | Unclear |
|
| ||||||
| Oláh et al. [ | 2009 | POPF rate 25%, reduction to 15%, alfa 5%, power of 80% | Sealed envelopes | Missing | Hospital stay | Low |
|
| ||||||
| Diener et al. [ | 2011 | POPF rate 35%, reduction of 15%, two-sided alfa 5%, power of 80% | Central randomisation system | The patient and the outcome assessor | POD 30 | Low |
|
| ||||||
| Frozanpor et al. [ | 2012 | POPF rate 40%, reduction to 0%, two-sided alfa 5%, power of 80% | Opaque sealed envelopes | Missing | POD 30 | Low |
|
| ||||||
| Hamilton et al. [ | 2012 | POPF rate 20%, reduction to 5%, two-sided alfa 5%, power of 80% | Random number generator | The patient and the outcome assessor | POD 30 | Low |
|
| ||||||
| Montorsi et al. [ | 2012 | POPF rate 30%, reduction to 15%, two-sided alfa 5%, power of 80% | Two separate randomization lists at each center (laparoscopic and open) | Missing | 2 months after discharge | Low |
|
| ||||||
| Carter et al. [ | 2013 | POPF rate 30%, reduction to 15%, one-tailed test alfa 5%, power of 80% | Opaque sealed envelopes | Missing | May 2012 (7 months after trial closure) | Low |
POD: postoperative day; POPF: postoperative pancreatic fistula.
Ongoing trials on surgical techniques in distal pancreatectomy.
| Department, Country | Study number | Commencement | Planned | Intervention |
|---|---|---|---|---|
| University of Heildelberg, Heildeberg, Germany [ | DRKS00000546 | December 2010 | 150 | Coverage with falciform ligament versus standard technique |
|
| ||||
| Mayo Clinic, Rochester, MN, USA | NCT01051856 | December 2009 | 400 | Stapler closure with bioabsorbable staple line reinforcement (SEAMGUARD) versus radiofrequency ablation device (Tissuelink) |
|
| ||||
| Seoul National University Hospital, Seoul, Republic of Korea | NCT01550406 | November 2011 | 150 | TachoComb (collagen sheet coated with fibrinogen) versus polyglycolic acid (biodegradable, thermoplastic polymer) |
|
| ||||
| Wakayama University, Wakayama, Japan | NCT01384617 | June 2011 | 136 | Roux-en-Y anastomosis versus stapler closure |
|
| ||||
| Massachusetts General Hospital, Massachusetts, USA | NCT00671463 | April 2008 | Withdrawn | Placing a stent into the pancreatic duct prior to surgery |